- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.10 Å
- Oligo State
- homo-dimer
- Ligands
- 4 x GOL: GLYCEROL(Non-functional Binders)
- 2 x CA: CALCIUM ION(Non-covalent)
CA.2: 5 residues within 4Å:- Chain A: R.109, D.275, D.279
- Chain B: D.252
- Ligands: AKG.3
5 PLIP interactions:2 interactions with chain A, 1 interactions with chain B, 2 Ligand-Water interactions- Metal complexes: A:D.275, A:D.279, B:D.252, H2O.2, H2O.4
CA.8: 5 residues within 4Å:- Chain A: D.252
- Chain B: R.109, D.275, D.279
- Ligands: AKG.9
5 PLIP interactions:2 interactions with chain B, 1 interactions with chain A, 2 Ligand-Water interactions- Metal complexes: B:D.275, B:D.279, A:D.252, H2O.7, H2O.9
- 2 x AKG: 2-OXOGLUTARIC ACID(Non-covalent)
AKG.3: 14 residues within 4Å:- Chain A: T.77, S.94, N.96, R.100, R.109, Y.139, D.275, A.308
- Chain B: K.212, T.214, I.215, D.252
- Ligands: CA.2, NDP.5
8 PLIP interactions:6 interactions with chain A, 2 interactions with chain B- Hydrogen bonds: A:T.77, A:S.94, A:N.96, A:Y.139, B:K.212
- Salt bridges: A:R.100, A:R.109
- Water bridges: B:T.214
AKG.9: 14 residues within 4Å:- Chain A: K.212, T.214, I.215, D.252
- Chain B: T.77, S.94, N.96, R.100, R.109, Y.139, D.275, A.308
- Ligands: CA.8, NDP.11
8 PLIP interactions:2 interactions with chain A, 6 interactions with chain B- Hydrogen bonds: A:K.212, B:T.77, B:S.94, B:N.96, B:Y.139
- Water bridges: A:T.214
- Salt bridges: B:R.100, B:R.109
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
NDP.5: 29 residues within 4Å:- Chain A: E.17, K.72, A.74, T.75, I.76, T.77, R.82, N.96, L.288, G.289, A.307, A.308, H.309, G.310, T.311, V.312, T.313, R.314, H.315, T.327, N.328, D.375
- Chain B: T.214, L.250, D.252, D.253, Q.257, K.260
- Ligands: AKG.3
30 PLIP interactions:24 interactions with chain A, 6 interactions with chain B- Hydrogen bonds: A:K.72, A:T.75, A:T.75, A:T.75, A:T.77, A:T.77, A:R.82, A:R.82, A:N.96, A:G.310, A:G.310, A:T.311, A:V.312, A:R.314, A:R.314, A:N.328, A:N.328, B:D.253, B:Q.257
- Water bridges: A:T.313, A:R.314, A:H.315, A:H.315, A:H.315, B:D.253, B:D.253, B:K.260
- Salt bridges: A:R.314, A:H.315, B:K.260
NDP.11: 29 residues within 4Å:- Chain A: T.214, L.250, D.252, D.253, Q.257, K.260
- Chain B: E.17, K.72, A.74, T.75, I.76, T.77, R.82, N.96, L.288, G.289, A.307, A.308, H.309, G.310, T.311, V.312, T.313, R.314, H.315, T.327, N.328, D.375
- Ligands: AKG.9
30 PLIP interactions:24 interactions with chain B, 6 interactions with chain A- Hydrogen bonds: B:K.72, B:T.75, B:T.75, B:T.75, B:T.77, B:T.77, B:R.82, B:R.82, B:N.96, B:G.310, B:G.310, B:T.311, B:V.312, B:R.314, B:R.314, B:N.328, B:N.328, A:Q.257
- Water bridges: B:T.313, B:R.314, B:H.315, B:H.315, B:H.315, A:D.253, A:D.253, A:D.253, A:K.260
- Salt bridges: B:R.314, B:H.315, A:K.260
- 2 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Reinbold, R. et al., Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun (2022)
- Release Date
- 2022-07-13
- Peptides
- Isocitrate dehydrogenase [NADP] cytoplasmic: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CB
C
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.10 Å
- Oligo State
- homo-dimer
- Ligands
- 4 x GOL: GLYCEROL(Non-functional Binders)
- 2 x CA: CALCIUM ION(Non-covalent)
- 2 x AKG: 2-OXOGLUTARIC ACID(Non-covalent)
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 2 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Reinbold, R. et al., Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun (2022)
- Release Date
- 2022-07-13
- Peptides
- Isocitrate dehydrogenase [NADP] cytoplasmic: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CB
C